GlassScriptPhysician profile
Marcelli Pascal-Rodriguez
NPI 1518480045
$2,641.88
in general payments reported to CMS, 2019-2025
22 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $499 · 2023: $929 · 2024: $451 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.75 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $379.05 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $289.79 | 2021-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $215.24 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.59 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $108.39 | 2021-2023 | Trintellix |
| Alkermes, INC. | $81.86 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $70.82 | 2022-2023 | Azstarys |
| Tris Pharma INC | $67.21 | 2022-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $60.50 | 2021-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $49.45 | 2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $45.82 | 2024 | |
| Almatica Pharma LLC | $40.32 | 2022-2023 | Gralise |
| Lundbeck LLC | $38.68 | 2021 | |
| Avanir Pharmaceuticals, INC. | $33.63 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $31.28 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $29.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.94 | 2025 | Cobenfy |
| Musculoskeletal Transplant Foundation INC. | $17.70 | 2025 | |
| Revance Therapeutics, INC. | $15.97 | 2024 | Daxxify |
| Neos Therapeutics, LP | $15.02 | 2022 | |
| Tms Neurohealth Centers INC. | $9.34 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelli Pascal-Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.